| Ytd | -72.80% | |
| 1y | -72.34% |
| Open | 0.33 | Prev Close | 0.33 | Low | 0.33 | High | 0.33 | Mkt Cap | 29.74M |
| Vol | 0.00 | Avg Vol | 2.85M | EPS | -0.78 | P/E | -0.42 | Forward P/E | -2.02 |
| Beta | 0.15 | Short Ratio | 1.78 | Inst. Own | 81.58% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 0.27 | 200-d Avg | 0.74 | 1yr Est | 3.35 |
ALLK News
NEW YORK , April 2, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), h
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Allakos (Nasdaq: ALLK) for possible brea
SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (“Allakos”) (Nasdaq: ALLK), a bi
SAN CARLOS, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK),
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a biotechno
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is i
On Monday, Allakos Inc (NASDAQ: ALLK) revealed topline results from its phase 1 clinical trial of AK
– AK006 did not demonstrate therapeutic activity in CSU –– Allakos will discontinue further developm
NEW YORK , Dec. 19, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inve
Allakos (ALLK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the com
Allakos shifted focus to AK006 in 2024 after lirentelimab's failure in phase 2 trials for atopic der
SAN CARLOS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a
– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor
SAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a
LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights li
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in pr
LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights li
LOS ANGELES, CA / ACCESSWIRE / June 24, 2024 / The Schall Law Firm, a national shareholder rights li
LOS ANGELES, CA / ACCESSWIRE / June 23, 2024 / The Schall Law Firm, a national shareholder rights li
On Tuesday, 647 companies set new 52-week lows.
During the session on Thursday, 461 stocks hit new 52-week lows.
Gainers
During Thursday, 849 stocks hit new 52-week lows.
On Friday, 431 companies hit new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.